The stock fell 10.92% to $9.30. NovaBay Pharmaceuticals, Inc. (NYSE: NBY)’s third-quarter net sales fell from $3.1 million in 2018 to $1.6 million in 2019. The net loss for the quarter narrowed from 9 …

More The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera’s Reverse Split, 2 Biotechs To Debut Videos